Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Outpatient Treatment of SARS-CoV-2: Practical Considerations
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: May 25, 2022 Expiration: May 24, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.
person default
Michael G. Ison, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply best practices in implementing timely treatment for COVID-19 based on current evidence and guidelines

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Michael G. Ison, MD, MS

Professor
Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Michael G. Ison, MD, MS, has disclosed that he has received funds for research support from GlaxoSmithKline and Pulmocide; has received consulting fees from Adagio, ADMA Biologics, AlloVir, Atea, Cidara, Genentech/Roche, Janssen, Shionogi, Takeda, and Viracor Eurofins; has served as an unpaid consultant for Romark; and has served on the Data and Safety Monitoring Board for Adamis, Allovir, CSL Behring, Janssen, Merck, Sequiris, Takeda, and Talaris.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, MSN, FNP-BC, has no relevant conflicts of interest to report.
Sarah Anderson, PharmD
Scientific Director
Sarah Anderson, PharmD, has disclosed that she has individual publicly traded stocks and stock options with Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with COVID-19.

Goal

The goal of this activity is to enable learners to continuously update their clinical management strategies to provide the most appropriate timely treatment for each patient with COVID-19.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-143-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 25, 2022, through May 24, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Outpatient Treatment of SARS-CoV-2: Practical Considerations
  • CME
  • CE

Loading...
Join Michael G. Ison, MD, MS, as he reviews the latest recommendations and data supporting currently available outpatient treatment options for COVID-19 and provides a roadmap for implementation of the different strategies.
person default
Michael G. Ison, MD, MS
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: May 25, 2022 Expiration: May 24, 2023

Related Content

Download slides reviewing the latest data and guidance on COVID-19 treatments, including authorized and investigational agents, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 10, 2022

Download slides reviewing the latest data and guidance on COVID-19 symptoms and clinical manifestations, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 9, 2022

Download slides reviewing the latest data and guidance on COVID-19 vaccinations, including authorized and investigational agents, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 8, 2022

Download slides reviewing the latest data and guidance on COVID-19 prevention and treatment in special populations, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 8, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings